CN1110501C - 一种从海绵中提取的胆甾醇醋酸酯及制法 - Google Patents
一种从海绵中提取的胆甾醇醋酸酯及制法 Download PDFInfo
- Publication number
- CN1110501C CN1110501C CN 98122225 CN98122225A CN1110501C CN 1110501 C CN1110501 C CN 1110501C CN 98122225 CN98122225 CN 98122225 CN 98122225 A CN98122225 A CN 98122225A CN 1110501 C CN1110501 C CN 1110501C
- Authority
- CN
- China
- Prior art keywords
- compound
- silica gel
- column chromatography
- acetate
- gel column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims 2
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 title abstract 3
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 235000014347 soups Nutrition 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003208 petroleum Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- YEYCQJVCAMFWCO-UHFFFAOYSA-N 3beta-cholesteryl formate Natural products C1C=C2CC(OC=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 YEYCQJVCAMFWCO-UHFFFAOYSA-N 0.000 abstract 1
- 230000021736 acetylation Effects 0.000 abstract 1
- 238000006640 acetylation reaction Methods 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 241000243142 Porifera Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- -1 steroidal Chemical class 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000796466 Rhabdastrella Species 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本发明涉及一种从海绵中提取获得胆甾醇醋酸酯的方法,该新化合物被命名为:25(29)-亚甲基-26-甲基-26-乙基胆甾醇醋酸酯(Rhabdasterol acetate)化学结构式为:该化合物是由南海海绵经提取、分离、硅胶柱层析和重结晶及乙酰化过程而制得,不但具有新的化学结构而且具有较强的降血压和抗心率失常的作用,因此有良好的开发应用前景。
Description
本发明涉及一种从海绵中提取分离,并通过化学方法获得胆甾醇醋酸酯的方法。
海绵是最原始的多细胞动物之一,种类繁多,分布极广,以海产为主。我国南海地处热带和亚热带,海洋生物物种极为丰富,特别是海绵,约占世界总数的一半,人们已从海绵生物中发现了许多结构独特的有机化合物如:萜类、甾体、苷类、生物碱、多肽和聚醚类等,其中许多具有抗肿瘤、抗心血管病、抗菌和抗病毒等生理活性,不少化合物具有潜在的临床应用价值,特别是以这些化合物为模式经过化学结构的修饰,获得生理活性更强、毒性更低的有机化合物,更加引起关注。
本发明所述的胆甾醇醋酸酯化学名称为:25(29)-亚甲基-26-甲基-26-乙基胆甾醇醋酸酯(英文名称Rhabdasterol acetate),该化合物结构式为:
中国专利96122199.2所公开的胆甾醇在结构上的不同之处是增加一个乙酰基,减少一个氢原子,即原结构中氢原子被乙酰基所取代,该化合物的物理常数如下:
m.p.102~104℃;[α]D 20(CH2Cl2,C=9.76mg/ml,C=0.97)-44.6°;νmax KBr(cm-1):3438,2937,2823,1731,1641,1463,1371,1332,1249,1135,1039,962,887,833;δ1H(CDCl3):5.38(1H,d,J=4.5Hz,6-H),4.70(2H,S,29-H),4.61(1H,m,3α-H),2.03(3H,S,-OCH3),1.02(3H,S,19-CH3),1.00(3H,d,J=6.95Hz,30-CH3),0.95(3H,d,J=6.64Hz,21-CH3),0.84(3H,t,J=7.40,28-CH3),0.69(3H,S,18-CH3);δ13C(CDCl3):170.53(C=O),155.28(C25),139.65(C5),122.61(C6),107.08(C29),73.99(C3),56.68(C14),55.99(C17),50.80(C10),50.05(-OCH3),42.35(C4),41.70(C13),39.74(C26),38.12(C12),36.99(C1),36.59(C20),35.76(C22),34.63(C7),31.88(C8),31.88(C9),30.39(C23),28.28(C2),28.16(C24),27.77(C27),24.26(C16),21.38(C15),21.03(C11),19.79(C19),19.28(C30),18.72(C21),11.94(C28),11.84(C18);m/z:408(15.4),394(61.7),296(100),147(54.62),145(60.33),81(71.6),69(54.6),55(71.4),43(77.6).
该化合物的提取、分离以及化学反应的方法包括如下过程:
海绵用乙醇提取,提取物经浓缩至浆状物,分散在水中,以乙酸乙酯萃取,萃取物经反复硅胶柱层析,通过丙酮-甲醇混合液二次结晶得针状晶体,再经乙酰化反应获得本发明所述的胆甾醇醋酸酯化合物。
本发明所述化合物的药理作用由中山大学药学系测试,初步药效学试验表明:
1.该化合物对正常大鼠的血压、心率有一定的作用,在4mg/kg药量下,降压率达4.1%,心率变化率为4.2%。
2.该化合物对豚鼠右心房自律性有一定的影响,在终浓度0.06mg/ml下,收缩力最大反应为-4.3%。
由上述的试验数据表明,本发明所述的化合物不但具有新的结构,而且对动物正常血压、心率失常现象有较强的影响,因此该化合物具有重要的理论价值和应用前景。
实施例:
1.南海海绵Rhabdastrella sp.晒干(3.0kg),切碎后用95%工业乙醇(5kg)于室温下抽提三次,合并抽提物并减压浓缩至浆状物,将浆状物均匀分散于500ml蒸馏水中,以乙酸乙酯(500ml)萃取三次,合并萃取物并减压浓缩得棕色浆状物71g。该浆状物经硅胶(200g,青岛海洋化工厂,硅胶H,10~40μ)柱层析(φ=3.6×48),以500ml不同比例的乙酸乙酯-石油醚(10%,15%,20%,30%)和500ml 30%丙酮-石油醚进行梯度淋洗,获得五个不同极性的洗出液,将其中15%的乙酸乙酯-石油醚组分经减压浓缩得固体物2.8g,再进行硅胶(120g,青岛海洋化工分厂,300-400目)柱层析(φ=2.4×48cm,洗脱剂:15%乙酸乙酯-石油醚),获得粗产物2.1g,将此粗产物用丙酮-甲醇在室温下进行二次重结晶,获得无色针状晶体350mg。经红外,质谱和核磁共振谱等数据确定此化合物为25(29)-亚甲基-26-甲基-26-乙基胆甾醇(1)。2.乙酰化作用①在25ml单口圆底烧瓶中加入113.0mg化合物(1),1.5ml醋酸酐,1.5ml吡啶。在室温密封体系下,磁搅拌反应3小时(通过TLC判断反应已完全),减压除去溶剂和多余酸酐,再通过硅胶(10g,300~400目)柱层析(φ=1.2×43cm,洗脱剂:2%乙酸乙酯-石油醚)获得化合物(2)103.2mg,以胆甾醇计算产率为83.2%。②在25ml单口圆底烧瓶中加入115.0mg化合物(1),1.5ml醋酸酐,1.5ml吡啶。控制温度在65℃下,装上氯化钙干燥管,磁搅拌反应1小时(通过TLC判断反应已完全),减压除去吡啶和多余酸酐,再通过硅胶(10g,300~400目)柱层析(φ=1.2×43cm,洗脱剂:2%乙酸乙酯-石油醚)获得化合物(2)112.0mg,产率为88.7%。经红外光谱,质谱和核磁共振谱等数据确定其化学结构为:
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 98122225 CN1110501C (zh) | 1998-11-26 | 1998-11-26 | 一种从海绵中提取的胆甾醇醋酸酯及制法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 98122225 CN1110501C (zh) | 1998-11-26 | 1998-11-26 | 一种从海绵中提取的胆甾醇醋酸酯及制法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1222525A CN1222525A (zh) | 1999-07-14 |
CN1110501C true CN1110501C (zh) | 2003-06-04 |
Family
ID=5227681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 98122225 Expired - Fee Related CN1110501C (zh) | 1998-11-26 | 1998-11-26 | 一种从海绵中提取的胆甾醇醋酸酯及制法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1110501C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100358516C (zh) * | 2004-12-07 | 2008-01-02 | 中国科学院大连化学物理研究所 | 一种多皱软磺酸在抗hiv-1病毒的药物中的应用 |
CN102225921B (zh) * | 2011-04-26 | 2013-04-24 | 中国人民解放军第二军医大学 | 一种环戊烷聚酮类化合物simplextone A及其用途 |
-
1998
- 1998-11-26 CN CN 98122225 patent/CN1110501C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1222525A (zh) | 1999-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100377546B1 (ko) | 효소적 방법에 의한 진세노사이드 컴파운드 케이의 제조방법 | |
Yoshida et al. | Perfectly regioselective acylation of a cardiac glycoside, digitoxin, via catalytic amplification of the intrinsic reactivity | |
Wang et al. | Production of ginsenoside F1 using commercial enzyme Cellulase KN | |
CN112409368B (zh) | 一类c-4位取代香豆素类化合物及其制备方法和应用 | |
CN102002031B (zh) | 芒果苷元的全化学合成方法 | |
Gold et al. | Synthesis and Reactions of Steroidal Quinols1 | |
Sofrenić et al. | Cytotoxic triterpenoids and triterpene sugar esters from the medicinal mushroom Fomitopsis betulina | |
Choudhary et al. | Biotransformation of adrenosterone by filamentous fungus, Cunninghamella elegans | |
Shan et al. | Synthesis of 3β, 7α, 11α-trihydroxy-pregn-21-benzylidene-5-en-20-one derivatives and their cytotoxic activities | |
Wonganan et al. | Potent vasorelaxant analogs from chemical modification and biotransformation of isosteviol | |
CN1110501C (zh) | 一种从海绵中提取的胆甾醇醋酸酯及制法 | |
Chen et al. | Biotransformation of terpenes from Stemodia maritima by Aspergillus niger ATCC 9142 | |
CN101434632B (zh) | 一种3α,7α-二羟基-5β-胆烷酸的制备方法 | |
Yang et al. | Three sesquiterpene compounds biosynthesised from artemisinic acid using suspension-cultured cells of Averrhoa carambola (Oxalidaceae) | |
Medici et al. | 7α-OH epimerisation of bile acids via oxido-reduction with Xanthomonas maltophilia | |
Gao et al. | Microbial transformation of 3β-acetoxypregna-5, 16-diene-20-one by Penicillium citrinum | |
Kasai et al. | Cycloartane glycosides from Trichosanthes tricuspidata | |
Cipolla et al. | Synthesis of stable analogues of glyceroglycolipids | |
EP1775304A1 (en) | Process for production of steroids | |
McPhail et al. | Structure and stereochemistry of eupaformonin, a novel cytotoxic sesquiterpene lactone from eupatorium formosanum hay. | |
CN104327034B (zh) | 5位和7位酯基儿茶素分子选择性制备方法 | |
Kim et al. | Microbial metabolites of 8-prenylnaringenin, an estrogenic prenylflavanone | |
JPH08291164A (ja) | ピリピロペン誘導体 | |
CN109206470B (zh) | 刺囊酸衍生物制备方法及医药新用途 | |
CN1217336A (zh) | 熊去氧胆酸立体选择性合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |